SLS
Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.00M | 7.60M | 1.90M | 0 | 0 | 0 | 0 | 0 | 9.32M |
| Net Income | (26.86M) | (30.88M) | (37.34M) | (41.30M) | (20.70M) | (16.76M) | (19.29M) | (27.67M) | (23.75M) | (23.55M) | (63.90M) | (36.61M) |
| EPS | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 | -10.92 | -157.72 | -521.91 | -933.13 | -411.55 | -1022.20 |
| Free Cash Flow | (28.39M) | (35.40M) | (36.91M) | (28.31M) | (26.02M) | (10.42M) | (17.64M) | (30.42M) | (10.99M) | (44.92M) | (48.31M) | (48.40M) |
| FCF / Share | -0.26 | -0.58 | -1.33 | -1.46 | -1.68 | -1.31 | -9.99 | -173.84 | -244.20 | -2495.61 | -2415.65 | -1351.46 |
| Operating CF | (28.39M) | (35.40M) | (31.41M) | (23.81M) | (26.02M) | (10.42M) | (17.64M) | (30.42M) | (10.99M) | (44.91M) | (48.16M) | (42.87M) |
| Total Assets | 78.34M | 19.43M | 6.22M | 20.94M | 26.43M | 46.05M | 16.61M | 16.91M | 33.53M | 65.81M | 82.14M | 80.49M |
| Total Debt | 1.00M | 1.00M | 906,000 | 945,000 | 808,000 | 991,000 | 217,000 | 0 | 10.99M | 16.40M | 4.74M | 8.40M |
| Cash & Equiv | 71.89M | 13.89M | 2.53M | 17.12M | 21.45M | 35.30M | 7.28M | 5.34M | 2.32M | 18.08M | 29.73M | 23.65M |
| Book Value | 70.87M | 9.46M | (7.98M) | 4.85M | 20.35M | 27.96M | 6.09M | 5.25M | 2.07M | 28.66M | 13.51M | 37.06M |
| Return on Equity | -0.38 | -3.26 | N/A | -8.51 | -1.02 | -0.60 | -3.17 | -5.28 | -11.48 | -0.82 | -4.73 | -0.99 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.61M) | (8.41M) | (7.66M) | (6.79M) | (6.60M) | (5.81M) | (6.74M) | (7.11M) | (7.47M) | (9.57M) | (8.14M) | (9.27M) |
| EPS | -0.05 | -0.05 | -0.05 | -0.06 | -0.07 | -0.07 | -0.09 | -0.10 | -0.13 | -0.21 | -0.26 | -0.33 |
| Free Cash Flow | (7.59M) | (8.85M) | (4.92M) | (7.07M) | (7.33M) | (9.07M) | (7.15M) | (7.81M) | (9.68M) | (10.76M) | (10.32M) | (9.89M) |
| FCF / Share | -0.04 | -0.05 | -0.03 | -0.07 | -0.08 | -0.10 | -0.10 | -0.11 | -0.17 | -0.24 | -0.34 | -0.35 |
| Operating CF | (7.59M) | (8.85M) | (4.92M) | (7.07M) | (7.33M) | (9.07M) | (7.15M) | (7.81M) | (9.68M) | (10.76M) | (4.83M) | (6.89M) |
| Total Assets | 145.38M | 114.18M | 78.34M | 51.55M | 32.30M | 34.96M | 19.43M | 26.50M | 15.12M | 24.43M | 6.22M | 8.09M |
| Total Debt | 737,000 | 871,000 | 1.00M | 599,000 | 737,000 | 870,000 | 1.00M | 576,000 | 692,000 | 801,000 | 906,000 | 644,000 |
| Cash & Equiv | 138.44M | 107.20M | 71.89M | 44.42M | 25.30M | 28.40M | 13.89M | 21.03M | 9.15M | 18.41M | 2.53M | 3.97M |
| Book Value | 137.66M | 107.41M | 70.87M | 45.63M | 26.15M | 27.76M | 9.46M | 15.89M | 2.91M | 9.68M | (7.98M) | (3.83M) |
| Return on Equity | -0.07 | -0.08 | -0.11 | -0.15 | -0.25 | -0.21 | -0.71 | -0.45 | -2.56 | -0.99 | N/A | N/A |
